Publication CAMELOT - Jilg N, Top Antivir Med (2022) (results posted on registry)
Funding: Not reported/unclear
Conflict of interest: *
Blinding: quadruple blinding
Multicenter / USA |
Follow-up duration (days): 28
200 mg orally 4 times a day for 14 days
|Characteristics of participants|
Mean age : NR
Severity : Mild: n= 295/ Asymptomatic: n=*
Number of vaccinated participants: NR
|In the register|
Disease Progression at Day 28 [ Time Frame: 28 days ] Disease progression will be defined as the number of participants requiring hospitalization (including emergency room visit) or who die due to any cause within 28 days of randomization.
|In the report|
Hospitalization or death within 28 days
Yes. In English
Data-sharing willing stated in the publication:
|Risk of bias
The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review
This is an unpublished trial whose results have been reported in ClinicalTrials.gov. The trial registry, protocol and statistical analysis plan were used in data extraction and assessment of risk of bias. The trial was registered prospectively and no important changes were made to primary or secondary outcomes after recruitment start. The trial (n=295) achieved its target sample size (n=300).
This study was updated on January 26th, 2023 with data extracted from the published abstract.